Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, T. Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

Research output: Article

11 Citations (Scopus)

Abstract

The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). Results showed that BV significantly improved progression-free survival (PFS) vs placebo plus best supportive care alone. At 5-year follow-up, BV continued to provide patients with sustained PFS benefit; 5-year PFS was 59% (95% confidence interval [CI], 51-66) with BV vs 41% (95% CI, 33-49) with placebo (hazard ratio [HR], 0.521; 95% CI, 0.379-0.717). Similarly, patients with ‡2 risk factors in the BV arm experienced significantly higher PFS at 5 years than patients in the placebo arm (HR, 0.424; 95% CI, 0.302-0.596). Upfront consolidation with BV significantly delayed time to second subsequent therapy, an indicator of ongoing disease control, vs placebo. Peripheral neuropathy, the most common adverse event in patients receiving BV, continued to improve and/or resolve in 90% of patients. In summary consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated. Physicians should consider each patient's HL risk factor profile when making treatment decisions.

Original languageEnglish
Pages (from-to)2639-2642
Number of pages4
JournalBlood
Volume132
Issue number25
DOIs
Publication statusPublished - dec. 20 2018

Fingerprint

Hodgkin Disease
Disease-Free Survival
Recurrence
Placebos
Confidence Intervals
Hematopoietic Stem Cell Transplantation
Stem cells
Consolidation
Hazards
Disease control
cAC10-vcMMAE
Peripheral Nervous System Diseases
Decision Making
Therapeutics
Physicians

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., ... Sweetenham, J. (2018). Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood, 132(25), 2639-2642. https://doi.org/10.1182/blood-2018-07-861641

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. / Moskowitz, Craig H.; Walewski, Jan; Nademanee, Auayporn; Masszi, T.; Agura, Edward; Holowiecki, Jerzy; Abidi, Muneer H.; Chen, Andy I.; Stiff, Patrick; Viviani, Simonetta; Bachanova, Veronika; Sureda, Anna; McClendon, Teresa; Lee, Connie; Lisano, Julie; Sweetenham, John.

In: Blood, Vol. 132, No. 25, 20.12.2018, p. 2639-2642.

Research output: Article

Moskowitz, CH, Walewski, J, Nademanee, A, Masszi, T, Agura, E, Holowiecki, J, Abidi, MH, Chen, AI, Stiff, P, Viviani, S, Bachanova, V, Sureda, A, McClendon, T, Lee, C, Lisano, J & Sweetenham, J 2018, 'Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse', Blood, vol. 132, no. 25, pp. 2639-2642. https://doi.org/10.1182/blood-2018-07-861641
Moskowitz, Craig H. ; Walewski, Jan ; Nademanee, Auayporn ; Masszi, T. ; Agura, Edward ; Holowiecki, Jerzy ; Abidi, Muneer H. ; Chen, Andy I. ; Stiff, Patrick ; Viviani, Simonetta ; Bachanova, Veronika ; Sureda, Anna ; McClendon, Teresa ; Lee, Connie ; Lisano, Julie ; Sweetenham, John. / Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. In: Blood. 2018 ; Vol. 132, No. 25. pp. 2639-2642.
@article{e08cf2fe0e87419f90c006e9cf4e1032,
title = "Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse",
abstract = "The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). Results showed that BV significantly improved progression-free survival (PFS) vs placebo plus best supportive care alone. At 5-year follow-up, BV continued to provide patients with sustained PFS benefit; 5-year PFS was 59{\%} (95{\%} confidence interval [CI], 51-66) with BV vs 41{\%} (95{\%} CI, 33-49) with placebo (hazard ratio [HR], 0.521; 95{\%} CI, 0.379-0.717). Similarly, patients with ‡2 risk factors in the BV arm experienced significantly higher PFS at 5 years than patients in the placebo arm (HR, 0.424; 95{\%} CI, 0.302-0.596). Upfront consolidation with BV significantly delayed time to second subsequent therapy, an indicator of ongoing disease control, vs placebo. Peripheral neuropathy, the most common adverse event in patients receiving BV, continued to improve and/or resolve in 90{\%} of patients. In summary consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated. Physicians should consider each patient's HL risk factor profile when making treatment decisions.",
author = "Moskowitz, {Craig H.} and Jan Walewski and Auayporn Nademanee and T. Masszi and Edward Agura and Jerzy Holowiecki and Abidi, {Muneer H.} and Chen, {Andy I.} and Patrick Stiff and Simonetta Viviani and Veronika Bachanova and Anna Sureda and Teresa McClendon and Connie Lee and Julie Lisano and John Sweetenham",
year = "2018",
month = "12",
day = "20",
doi = "10.1182/blood-2018-07-861641",
language = "English",
volume = "132",
pages = "2639--2642",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

AU - Moskowitz, Craig H.

AU - Walewski, Jan

AU - Nademanee, Auayporn

AU - Masszi, T.

AU - Agura, Edward

AU - Holowiecki, Jerzy

AU - Abidi, Muneer H.

AU - Chen, Andy I.

AU - Stiff, Patrick

AU - Viviani, Simonetta

AU - Bachanova, Veronika

AU - Sureda, Anna

AU - McClendon, Teresa

AU - Lee, Connie

AU - Lisano, Julie

AU - Sweetenham, John

PY - 2018/12/20

Y1 - 2018/12/20

N2 - The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). Results showed that BV significantly improved progression-free survival (PFS) vs placebo plus best supportive care alone. At 5-year follow-up, BV continued to provide patients with sustained PFS benefit; 5-year PFS was 59% (95% confidence interval [CI], 51-66) with BV vs 41% (95% CI, 33-49) with placebo (hazard ratio [HR], 0.521; 95% CI, 0.379-0.717). Similarly, patients with ‡2 risk factors in the BV arm experienced significantly higher PFS at 5 years than patients in the placebo arm (HR, 0.424; 95% CI, 0.302-0.596). Upfront consolidation with BV significantly delayed time to second subsequent therapy, an indicator of ongoing disease control, vs placebo. Peripheral neuropathy, the most common adverse event in patients receiving BV, continued to improve and/or resolve in 90% of patients. In summary consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated. Physicians should consider each patient's HL risk factor profile when making treatment decisions.

AB - The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). Results showed that BV significantly improved progression-free survival (PFS) vs placebo plus best supportive care alone. At 5-year follow-up, BV continued to provide patients with sustained PFS benefit; 5-year PFS was 59% (95% confidence interval [CI], 51-66) with BV vs 41% (95% CI, 33-49) with placebo (hazard ratio [HR], 0.521; 95% CI, 0.379-0.717). Similarly, patients with ‡2 risk factors in the BV arm experienced significantly higher PFS at 5 years than patients in the placebo arm (HR, 0.424; 95% CI, 0.302-0.596). Upfront consolidation with BV significantly delayed time to second subsequent therapy, an indicator of ongoing disease control, vs placebo. Peripheral neuropathy, the most common adverse event in patients receiving BV, continued to improve and/or resolve in 90% of patients. In summary consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated. Physicians should consider each patient's HL risk factor profile when making treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=85058779535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058779535&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-07-861641

DO - 10.1182/blood-2018-07-861641

M3 - Article

C2 - 30266774

AN - SCOPUS:85058779535

VL - 132

SP - 2639

EP - 2642

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -